Oral tablets of Alphintern® — Competitive Intelligence Brief

Oral tablets of Alphintern® (Oral tablets of Alphintern®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-steroidal anti-inflammatory drug (NSAID). Area: Rheumatology.

marketed Non-steroidal anti-inflammatory drug (NSAID) COX-2 Rheumatology Small molecule

Target snapshot

Oral tablets of Alphintern® (Oral tablets of Alphintern®) — Ain Shams University. Alphintern is a synthetic derivative of a natural compound that inhibits the activity of a specific enzyme.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oral tablets of Alphintern® TARGET	Oral tablets of Alphintern®	Ain Shams University	marketed	Non-steroidal anti-inflammatory drug (NSAID)	COX-2
Celebrex	celecoxib	Pfizer Inc. (originally Searle/Pharmacia)	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	COX-2	1998-12-31
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
Pranoprofen eye drops	Pranoprofen eye drops	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1, COX-2)
Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole	Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole	University of Chicago	marketed	NSAID + opioid analgesic + proton pump inhibitor combination	COX-1/COX-2 (ibuprofen); mu-opioid receptor (hydrocodone); H+/K+-ATPase (omeprazole)
Ropivacaine Ketorolac	Ropivacaine Ketorolac	University of Aarhus	marketed	Local anesthetic + NSAID combination	Voltage-gated sodium channels (ropivacaine); COX-1/COX-2 (ketorolac)
ASA	ASA	Biogen	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2036-05-27 — Celebrex · 10722456 · Formulation · US
• 2036-05-27 — Celebrex · 10799517 · Formulation · US
• 2036-05-27 — Celebrex · 9949990 · Formulation · US
• 2036-05-27 — Celebrex · 9795620 · Formulation · US
• 2036-05-27 — Celebrex · 9572819 · Formulation · US
• 2036-05-27 — Celebrex · 10376527 · Formulation · US

Sponsor landscape (Non-steroidal anti-inflammatory drug (NSAID) class)

1. Ain Shams University · 1 drug in this class
2. IBSA Institut Biochimique SA · 1 drug in this class
3. Insel Gruppe AG, University Hospital Bern · 1 drug in this class
4. Pfizer · 1 drug in this class
5. Rabin Medical Center · 1 drug in this class
6. Saglik Bilimleri Universitesi Gulhane Tip Fakultesi · 1 drug in this class
7. Shijiazhuang Yiling Pharmaceutical Co. Ltd · 1 drug in this class
8. Takeda · 1 drug in this class
9. Thomas Jefferson University · 1 drug in this class